Skip to main content Back to Top


Nimodipine Oral Solution

Products Affected - Description

    • Nymalize oral solution, Arbor, 30 mg/10 mL, unit-dose cup, 12 count, NDC 24338-0205-12 - discontinued
    • Nymalize oral solution, Arbor, 60 mg/20 mL, 473 mL bottle, 1 count, NDC 24338-0200-16 - discontinued
    • Nymalize oral solution, Arbor, 60 mg/20 mL, unit-dose cup, 12 count, NDC 24338-0200-12 - discontinued

Reason for the Shortage

    • Arbor Pharmaceuticals has a new formulation of Nymalize available in prefilled oral syringes.

Available Products

    • Nymalize oral solution, Arbor, 6 mg/1 mL, 10 mL prefilled oral syringe, 12 count, NDC 24338-0260-12
    • Nymalize oral solution, Arbor, 6 mg/1 mL, 5 mL prefilled oral syringe, 12 count, NDC 24338-0230-12


    • The contents of nimodipine capsules may be extracted into a syringe using an 18-gauge needle. Transfer the contents of the capsule to an oral syringe that is not compatible with intravenous (IV) connections to avoid accidental IV administration of nimodipine. The manufacturers of nimodipine capsules and the Institute for Safe Medication Practices (ISMP) both recommend labeling the syringe containing nimodipine for administration with the phrase, "For Oral Use Only." Once the contents are given via a nasogastric tube, wash the tube with 30 mL of 0.9% normal saline. More information can be found at the following links:
    • Nimodipine Capsule Manufacturer Package Inserts:
    • ISMP Oral Syringe Featured Article:


Updated May 26, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created November 21, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.